Viron Therapeutics, Inc.
http://www.vironinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Viron Therapeutics, Inc.
Roche’s New Obesity Play Shows Early Promise
CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.
Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D
As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.
Japan Results Roundup: Weak Yen Provides A Boost But Some Sales Challenges Emerge
The weak yen helped push up both global revenues and costs for major Japanese firms in the fiscal year ended 31 March, while good mainstay growth benefited Daiichi Sankyo and Astellas. Chugai meanwhile had a challenging start to its calendar financial year due to lower pandemic drug stockpiling.
Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs
C-suite leaders from Lilly, Roche and J&J spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice